U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06963827) titled 'A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition' on April 30.
Brief Summary: Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any act...